Lorlatinib/lorlatinib API 3922

Lorlatinib/lorlatinib (Lorlatinib) API 3922 is a highly effective third-generation ALK inhibitor with significant central nervous system penetration. Its CAS number is 1454846-35-5, it is called PF-06463922 in the clinical trial stage, and its structural formula is C21H19FN6O2. The purity of this API can reach over 99.9%, and an HPLC spectrum is provided. With the launch of lorlatinib, its English name was named Lorlatinib and sold under the trade name Lorbrena.

Lorlatinib is a tyrosine kinase inhibitor (TKI) primarily used to treat certain types of lung cancer. It was originally designed for anaplastic large cell lymphoma (ALCL) and non-small cell lung cancer (NSCLC, particularly in ALK-positive patients). Lorlatinib specifically targets the anaplastic kinase (ALK) fusion gene, which is present in about 5% of non-small cell lung cancer and leads to abnormal proliferation. This drug inhibits the growth and spread of tumor cells by blocking the ALK signaling pathway. Clinical studies have shown that lorlatinib can significantly improve patients' progression-free survival (PFS) and overall survival (OS) with relatively few side effects, especially compared with chemotherapy. However, like all medications, it may cause some adverse effects, such as diarrhea, fatigue, nausea, and visual problems, but most patients can manage this by adjusting the dose or using complementary medications.

As one of the treatment options for advanced lung cancer, lorlatinib provides new hope for patients with ALK-positive lung cancer, improving the quality of life and prolonging survival. With the advancement of scientific research, more indications and optimized medication strategies may be discovered in the future.